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Introduction
The clinical course of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis has a myriad of neurological and psychiatric features, such as delusions and hallucinations, but also agitation, disorganized thinking, affective lability and catatonia.
1,2
Surprisingly, 7.8% of the patients with schizophrenia or other psychotic disorders have serum antibodies for this disease. 3 Because psychiatric symptoms emerge in the early stages of anti-NMDAR encephalitis, 77%
of the patients are not seen in a general healthcare service before seeking treatment in a psychiatric department, 4 where this disease may be mistaken for primary psychiatric conditions, such as brief psychosis disorder, drug-induced psychosis or mania. 1, 5 Moreover, 4% of the patients present with isolated psychiatric symptoms. 6 As anti-NMDAR encephalitis is not initially suspected, the treatment of this potentially lethal disorder may be delayed. 
Case description
A 30-year-old Brazilian single male computer technician was taken to the hospital by his mother.
Two days before, he had suddenly begun behaving strangely: his speech included meaningless words and alternated with silence, insomnia and restlessness. His In the last days of evaluation before discharge, he remained disoriented and reported amnesia during hospitalization. Psychomotor agitation episodes became sparse, controlled due to the verbal support of family members, and autonomic episodes were rare. After discharge, the patient received three more doses of cyclophosphamide. He is currently being followed up in our outpatient service. He still has some degree of apathy, but takes only trazodone (150 mg/day) and prednisone (10 mg/day).
Comments
Anti-NMDAR encephalitis requires specific treatment and atypical agents to treat adult patients have been described in current literature: haloperidol (1-2 mg/day), olanzapine (5 mg/day), aripiprazole (2.5 mg/day) and risperidone (1 mg/day). 8, 9 In two cases of adolescents, van de Riet et al. 13 described the combination of haloperidol and risperidone, but neither the use of low doses nor slow titration prevented both patients from having extrapyramidal side effects.
Risperidone has been suggested as an early treatment for first episode psychotic disorders because it has less frequent extrapyramidal side effects than typical antipsychotics. 14 In our case, it was prescribed immediately before quetiapine, because the patient presented with agitation and because akathisia was conditions, such as malignant neuroleptic syndrome and respiratory failure, should be seen as confounding factors, as they may be outcomes of the disease itself or adverse drug effects. 15 Furthermore, a multidisciplinary approach is essential for the successful treatment of patients with anti-NMDAR encephalitis and the prevention of physical and cognitive sequelae.
8,9
This case report contributes information about the psychiatric management of a patient with anti-NMDAR encephalitis, a diagnosis with which psychiatrists should be familiar. 
